TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Aurena Laboratories Holding AB
Closing information (x1000 EUR)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
24,024
|
22,402
|
19,787 |
| Financial expenses |
443
|
271
|
148 |
| Earnings before taxes |
2,145
|
1,723
|
1,238 |
| EBITDA |
3,346
|
2,644
|
1,858 |
| Total assets |
20,648
|
19,472
|
17,737 |
| Current assets |
8,813
|
7,819
|
8,164 |
| Current liabilities |
4,300
|
4,028
|
4,791 |
| Equity capital |
11,552
|
10,559
|
9,355 |
| - share capital |
44
|
45
|
45 |
| Employees (average) |
86
|
79
|
76 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
55.9%
|
54.2%
|
52.7% |
| Turnover per employee |
279
|
284
|
260 |
| Profit as a percentage of turnover |
8.9%
|
7.7%
|
6.3% |
| Return on assets (ROA) |
12.5%
|
10.2%
|
7.8% |
| Current ratio |
205.0%
|
194.1%
|
170.4% |
| Return on equity (ROE) |
18.6%
|
16.3%
|
13.2% |
| Change turnover |
2,384
|
2,557
|
2,365 |
| Change turnover % |
11%
|
13%
|
14% |
| Chg. No. of employees |
7
|
3
|
0 |
| Chg. No. of employees % |
9%
|
4%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.